CVS Claims It’s on the Verge of Losing All Its Pharmacies in Tennessee

Why It Matters

The legislation could reshape pharmacy ownership models, jeopardize access to care for Tennessee residents, and set a precedent for other states targeting integrated PBM‑pharmacy insurers.

Key Takeaways

• Fair Rx Act bans PBM-owner pharmacies in Tennessee
• CVS would have to close >100 stores if law passes
• Potential loss of 2,000 jobs and 25 MinuteClinics
• CVS plans federal lawsuit citing Commerce Clause violation

Pulse Analysis

State‑level attempts to separate pharmacy benefit managers from retail pharmacy operations have accelerated as lawmakers argue that integrated models inflate drug prices. The Fair Rx Act in Tennessee follows a wave of similar proposals, reflecting growing political pressure to curb the market power of large health conglomerates. By targeting entities that own both a PBM and a health insurer, the bill aims to level the playing field for independent pharmacies, but critics contend it could reduce economies of scale that help lower costs for insurers and patients alike.

If enacted, the Fair Rx Act would compel CVS Health to shutter more than 100 pharmacies and 25 MinuteClinic sites across Tennessee, eliminating roughly 2,000 jobs. Beyond the immediate employment impact, the closures would diminish convenient access to pharmacists, especially in rural areas where CVS often serves as the primary point of care. The loss of MinuteClinics also threatens the availability of walk‑in primary care services, potentially increasing pressure on emergency departments and local clinics. For patients, the transition could mean longer travel times for prescriptions and reduced continuity of care.

CVS has announced plans to contest the law in federal court, arguing that it violates the Commerce Clause by interfering with interstate business operations. The company’s legal strategy echoes the Arkansas case, where a federal judge issued a preliminary injunction against a comparable statute. The outcome of Tennessee’s legal battle will be closely watched by the broader health‑care industry, as a ruling in favor of the state could embolden other jurisdictions to pursue similar restrictions, reshaping the competitive landscape for PBMs, insurers, and retail pharmacy chains nationwide.